PYRIDOSTIGMINE ( DrugBank: Pyridostigmine )


4 diseases
IDDisease name (Link within this page)Number of trials
3Spinal muscular atrophy3
6Parkinson disease3
11Myasthenia gravis8
256Muscle glycogenosis1

3. Spinal muscular atrophy


Clinical trials : 237 Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02941328
(ClinicalTrials.gov)
December 201530/9/2016SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4A Phase II, Mono-center, Placebo-controlled, Double-blind, Crossover Trial to Investigate Effect and Efficacy of Pyridostigmine in Dutch Patients With Spinal Muscular Atrophy Types 2, 3 and 4Spinal Muscular Atrophy;SMA;Kugelberg-Welander DiseaseDrug: Pyridostigmine;Drug: PlaceboUMC UtrechtNULLCompleted12 YearsN/AAll39Phase 2Netherlands
2EUCTR2011-004369-34-NL
(EUCTR)
22/04/201503/11/2014 SPACE trial SMA and Pyridostigmine in Adults and Children; Experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4 SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2, 3 and 4 - SPACE trial Proximal spinal muscular atrophy (SMA) is characterized by weakness of predominantly axial and proximal muscle groups and is caused by homozygous deletion of the survival motor neuron 1 (SMN1)-gene. There are 4 SMA types (type 1-4), with a descending order of severity. Age at onset and achieved motor milestones are the characteristics to define severity. Treatment of SMA is exclusively supportive.
MedDRA version: 17.1;Level: LLT;Classification code 10068209;Term: Spinal muscular atrophy adult onset;System Organ Class: 100000004850
MedDRA version: 17.1;Classification code 10051203;Term: Spinal muscular atrophy congenital;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: pyridostigmine bromide
Product Name: Mestinon
Product Code: RVG 03820
Universtiy Medical Center UtrechtNULLNot Recruiting Female: yes
Male: yes
45 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noNetherlands
3NCT02227823
(ClinicalTrials.gov)
July 201420/8/2014Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3Safety and Efficacy Study of Anti-cholinesterase Therapy on the Motor Functions in Patients With Spinal Muscular Atrophy Type 3.Spinal Muscular Atrophy Type 3Drug: Pyridostigmine BromideCentre Hospitalier Régional de la CitadelleNULLRecruiting6 YearsN/ABoth20Phase 2Belgium

6. Parkinson disease


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05603715
(ClinicalTrials.gov)
August 10, 202212/9/2022Pyridostigmine for the Treatment of Constipation in Parkinson DiseasePyridostigmine for the Treatment of Constipation in Parkinson DiseaseParkinson Disease;ConstipationDrug: Pyridostigmine BromideUniversity of Vermont Medical CenterNULLRecruiting18 YearsN/AAll16Phase 2United States
2EUCTR2012-000122-21-DK
(EUCTR)
10/08/201207/06/2012Improving the blood pressure regulating system in patients with parkinsons diseaseAcethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease Ortostatic hypotension in patients with Parkinsons disease
MedDRA version: 14.1;Level: PT;Classification code 10031127;Term: Orthostatic hypotension;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
Trade Name: Mestinon
Product Name: Mestinon
INN or Proposed INN: PYRIDOSTIGMINE BROMIDE
Other descriptive name: Mestinon
Department of Neurology, Roskilde HospitalNULLNot RecruitingFemale: yes
Male: yes
20Phase 2Denmark
3NCT01993680
(ClinicalTrials.gov)
June 201227/4/2012Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -TreatmentA Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's DiseaseAutonomic Disturbances in Parkinson's DiseaseDrug: Pyridostigmine bromide;Drug: fludrocortisoneChristian BaumannNULLCompleted50 Years80 YearsAll18Phase 2Switzerland

11. Myasthenia gravis


Clinical trials : 332 Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ITMCTR2200005637
2022-01-012021-06-20Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled TrialEfficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial Ocular myasthenia graviscontrast group:Pyridostigmine Bromide Tablets;Experimental group:Buzhong Yiqi Decoction;Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji'nan UniversityNULLRecruiting1880Bothcontrast group:27;Experimental group:27;China
2ChiCTR2100047506
2022-01-012021-06-20Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled TrialEfficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial Ocular myasthenia gravisExperimental group:Buzhong Yiqi Decoction;contrast group:Pyridostigmine Bromide Tablets;Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji’nan UniversityNULLRecruiting1880BothExperimental group:27;contrast group:27;China
3NCT04226170
(ClinicalTrials.gov)
April 8, 20219/1/2020Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia GravisA Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia GravisMyasthenia GravisDrug: DAS-001DAS-MG, IncNULLRecruiting18 YearsN/AAll24Phase 2United States
4NCT04768465
(ClinicalTrials.gov)
January 1, 202121/2/2021Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia GravisEffectiveness and Safety of Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis: A Real-world StudyMyasthenia GravisDrug: Pyridostigmine, Prednisone, Tacrolimus;Drug: Pyridostigmine, TacrolimusDa, Yuwei, M.D.NULLRecruiting18 YearsN/AAll160China
5NCT03510546
(ClinicalTrials.gov)
April 9, 20186/4/2018Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia GravisEffect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia GravisMyasthenia GravisDrug: Pyridostigmine;Drug: Placebo oral capsuleUniversity of AarhusAarhus University HospitalRecruiting18 Years90 YearsAll44Phase 4Denmark
6EUCTR2017-002599-15-DK
(EUCTR)
07/11/201707/07/2017Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis.Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis. Myasthenia Gravis
MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Myasthenia gravis and related conditions;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Mestinon
INN or Proposed INN: pyridostigmine
Other descriptive name: PYRIDOSTIGMINE
Aarhus UniversityNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Phase 4Denmark
7ChiCTR-OCC-13003090
2012-12-202013-03-02Research on micrornas expression of Myasthenia gravis and the relationship with TH1, TH2 cells secrete cytokinesResearch on micrornas expression of Myasthenia gravis and the relationship with TH1, TH2 cells secrete cytokines Myasthenia gravisexperimental group:Pyridostigmine Bromide;control group:nothing;The first affiliated hospital of Guangzhou university of Traditional Chinese medicineNULLCompleted1865Bothexperimental group:30;control group:30;China
8ChiCTR-TRC-13004125
2010-10-012013-06-08The study on the pathogenesis of spleen-kidney deficiency type myasthenia gravis and the interference effect of Jianji Ning Granule on the patientsThe study on the pathogenesis of spleen-kidney deficiency type myasthenia gravis and the interference effect of Jianji Ning Granule on the patients Myasthenia gravistrial:Jianji Ning Granule combined with olfactory pyridostigmine tablets ;Control:olfactory pyridostigmine tablets ;Longhua Hospital Affiliated to Shanghai University of traditional Chinese MedicineNULLCompleted1475Bothtrial:30;Control:30;I+2 (Phase 1+Phase 2)China

256. Muscle glycogenosis


Clinical trials : 180 Drugs : 133 - (DrugBank : 29) / Drug target genes : 25 - Drug target pathways : 105
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02357225
(ClinicalTrials.gov)
August 201523/1/2015A Pilot Study of Pyridostigmine in Pompe DiseaseEvaluation of Respiratory and Skeletal Muscle Functions in Response to Acetylcholinesterase Inhibitors in Pompe DiseasePompe DiseaseDrug: Pyridostigmine BromideUniversity of FloridaNULLTerminated8 Years60 YearsAll2Early Phase 1United States